10:49 AM EDT, 05/01/2024 (MT Newswires) -- BetterLife Pharma ( BETRF ) , which is developing non-hallucinogenic LSD-based therapeutics for mental disorders, on Wednesday said it has completed the first set of GLP (good laboratory practice) toxicology study of oral BETR-001 in animals which shows that the compound is "very well tolerated", even with repeat dosing at high doses.

According to a statement, BetterLife is now initiating the other nonclinical toxicology studies that will support the filing of BETR-001's IND (investigational new drug) application with the FDA and the initiation of human clinical trials.

The company has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.

Dr. Ahmad Doroudian, CEO of BetterLife, said, "BETR-001 is a unique non-hallucinogenic derivative of LSD, which we have shown has robust activity in animal depression and anxiety models without the burden of being hallucinogenic. "

Price: 0.11, Change: -0.01, Percent Change: -8.70